Vividion Therapeutics has announced plans to broaden its capabilities with the establishment of a new research and development (R&D) centre and corporate headquarters at San Diego in California, US.
Apollo Therapeutics has entered into a collaboration with the University of Oxford in the UK to propel drug discovery and development.
Lynch Regenerative Medicine (LRM) has closed its Series A financing round for the development and commercialisation of advanced skin rejuvenation and regeneration solutions.
Merck has initiated commercial manufacturing of its first Good Manufacturing Practices (GMP)-compliant manufacturing line for cell culture media (CCM) in China.
MSD (Merck & Co) has completed the acquisition of EyeBio, making it a wholly-owned subsidiary, and bolstering its ophthalmology portfolio.
The US Food and Drug Administration (FDA) has granted fast track designation for radiotherapeutics company Full-Life Technologies’ 225Ac-FL-020 to treat metastatic castration-resistant prostate cancer (mCRPC).
The US Food and Drug Administration (FDA) has granted approval for Verona Pharma’s Ohtuvayre (ensifentrine) as maintenance therapy for chronic obstructive pulmonary disease (COPD) in adults.
Singapore-based Juniper Biologics has secured the distribution rights for Caris Life Sciences' advanced solid tumour molecular profiling services in the Middle East and Africa (MEA).
UK-based Yellowstone Biosciences has announced its launch with a £16.5m investment from Syncona to develop soluble bispecific T-cell receptor (TCR)-based therapies.
Clinical-stage biotechnology company Iambic Therapeutics has secured $50m in its Series B extension financing round to bolster its pipeline comprising artificial intelligence (AI)-discovered clinical oncology programmes.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.